A 48-year-old woman from Bangalore with type 2 diabetes mellitus for 8 years is on metformin 1000 mg twice daily and gliclazide 80 mg once daily. Her HbA1c is 7.8%, fasting glucose 118 mg/dL. She reports occasional episodes of sweating, palpitations, and tremor in the afternoon (3–4 hours after lunch), which resolve after eating a snack. Her BMI is 26 kg/m², blood pressure 128/82 mmHg, and renal function is normal. What is the most likely cause of her symptoms, and what is the most appropriate modification to her current regimen?

Explanation

## Clinical Diagnosis ### Symptom Analysis **Key Point:** The symptom triad of sweating, palpitations, and tremor occurring 3–4 hours after lunch (when gliclazide peak action is maximum) strongly suggests **hypoglycemia** from excessive sulfonylurea effect. **High-Yield:** Symptoms of hypoglycemia are: - **Adrenergic (early):** Tremor, palpitations, sweating, anxiety, tachycardia - **Neuroglycopenic (late):** Confusion, seizures, loss of consciousness This patient's afternoon symptoms are classic adrenergic hypoglycemia, not metabolic derangement or neuropathy. ### Why Hypoglycemia, Not Lactic Acidosis? | Feature | Lactic Acidosis | Hypoglycemia (This Case) | |---|---|---| | **Onset** | Insidious, progressive over hours/days | Acute, episodic, 3–4 hrs post-meal | | **Symptoms** | Dyspnea, altered mental status, Kussmaul respiration | Tremor, palpitations, sweating, relief with food | | **Risk factors** | Renal impairment, sepsis, liver disease | Excessive insulin/sulfonylurea | | **This patient** | Normal renal function, no sepsis | Symptoms resolve with snack ✓ | **Clinical Pearl:** Gliclazide has a rapid onset (30–60 min) and peak action at 2–3 hours, making afternoon hypoglycemia common when combined with metformin in a patient with good glycemic control (HbA1c 7.8%). ### Appropriate Management **Mnemonic:** **REDUCE-SWITCH** for sulfonylurea hypoglycemia: - **R**educe dose (first-line) - **E**valuate meal timing and composition - **D**iscontinue if recurrent despite dose reduction - **U**se alternative agent (DPP-4, SGLT2i, GLP-1) - **C**ontinue metformin (safe, no hypoglycemia risk) - **E**ducate on hypoglycemia recognition **Best option:** Reduce gliclazide dose (e.g., to 40 mg once daily) OR switch to a non-insulin secretagogue agent such as: - DPP-4 inhibitor (sitagliptin 100 mg OD) — glucose-dependent, minimal hypoglycemia risk - SGLT2 inhibitor (empagliflozin 10 mg OD) — weight-neutral, cardioprotective - GLP-1 agonist — weight loss, cardiovascular benefit Metformin should be continued (no hypoglycemia risk, HbA1c benefit). ## Why Each Distractor Is Incorrect | Option | Why Wrong | |---|---| | **Lactic acidosis + pioglitazone** | Symptoms are acute and episodic (hypoglycemia), not lactic acidosis. Pioglitazone causes weight gain and fluid retention—inappropriate here. | | **Thyroid dysfunction** | No signs of hypo- or hyperthyroidism (normal vital signs, no weight change, no fatigue). Thyroid dysfunction causes gradual, persistent symptoms, not episodic afternoon episodes. | | **Diabetic neuropathy** | Neuropathy causes chronic, progressive pain/numbness, not acute episodic adrenergic symptoms. Pregabalin does not address the underlying hypoglycemia. | [cite:KD Tripathi 8e Ch 28; Harrison 21e Ch 417]